Fiorica, F.; Buttigliero, C.; Grigolato, D.; Muraro, M.; Turco, F.; Munoz, F.; Tucci, M.
Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis. Curr. Oncol. 2022, 29, 9511-9524.
https://doi.org/10.3390/curroncol29120747
AMA Style
Fiorica F, Buttigliero C, Grigolato D, Muraro M, Turco F, Munoz F, Tucci M.
Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis. Current Oncology. 2022; 29(12):9511-9524.
https://doi.org/10.3390/curroncol29120747
Chicago/Turabian Style
Fiorica, Francesco, Consuelo Buttigliero, Daniela Grigolato, Marco Muraro, Fabio Turco, Fernando Munoz, and Marcello Tucci.
2022. "Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis" Current Oncology 29, no. 12: 9511-9524.
https://doi.org/10.3390/curroncol29120747
APA Style
Fiorica, F., Buttigliero, C., Grigolato, D., Muraro, M., Turco, F., Munoz, F., & Tucci, M.
(2022). Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis. Current Oncology, 29(12), 9511-9524.
https://doi.org/10.3390/curroncol29120747